| Ytd | 65.04% | |
| 1y | 40.19% |
| Open | 12.95 | Prev Close | 12.93 | Low | 12.78 | High | 13.50 | Mkt Cap | 1.40B |
| Vol | 1.28M | Avg Vol | 1.70M | EPS | -1.35 | P/E | -10.00 | Forward P/E | -6.76 |
| Beta | 1.01 | Short Ratio | 11.29 | Inst. Own | 114.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 9.70 | 200-d Avg | 10.57 | 1yr Est | 20.29 |
ORIC News
Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, I
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, wit
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market sess
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nas
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, I
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 g
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, R
On Friday, 1043 companies hit new 52-week lows.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30)
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)